- Report
- November 2024
- 150 Pages
Global
From €4650EUR$4,850USD£3,885GBP
- Report
- October 2024
- 194 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- July 2022
- 203 Pages
Global
From €6855EUR$7,150USD£5,727GBP
- Report
- January 2023
- 124 Pages
From €3307EUR$3,450USD£2,764GBP
- Report
- January 2023
- 134 Pages
Africa, Middle East
From €3307EUR$3,450USD£2,764GBP
- Report
- January 2023
- 160 Pages
Asia Pacific
From €3307EUR$3,450USD£2,764GBP
- Report
- January 2023
- 146 Pages
North America
From €3307EUR$3,450USD£2,764GBP
- Report
- January 2023
- 153 Pages
Europe
From €3307EUR$3,450USD£2,764GBP
- Report
- October 2022
- 209 Pages
Global
From €4266EUR$4,450USD£3,565GBP
- Report
- April 2025
- 50 Pages
Global
From €2540EUR$2,650USD£2,123GBP
Darifenacin is a drug used to treat overactive bladder, a condition characterized by urinary urgency, frequency, and incontinence. It is a muscarinic receptor antagonist, meaning it works by blocking the action of acetylcholine, a neurotransmitter that causes bladder contractions. Darifenacin is available in both immediate-release and extended-release formulations. It is typically taken once daily, with or without food. Common side effects include dry mouth, constipation, and blurred vision.
Darifenacin is used to treat a variety of urological disorders, including overactive bladder, urinary incontinence, and urinary retention. It is also used to reduce the risk of urinary tract infections. Darifenacin is available in generic and brand-name formulations.
Several companies manufacture and market Darifenacin, including Astellas Pharma, Inc., Mylan Pharmaceuticals, Inc., and Teva Pharmaceuticals USA, Inc. Show Less Read more